Nitroxide pirolin reduces oxidative stress generated by doxorubicin and docetaxel in blood plasma of rats bearing mammary tumor

Journal of Physiology and Pharmacology

Volumn 63, Issue 2, 2012, Pages 153-163

  Tabaczar, S ^a   Koceva Chyla, A ^a   Czepas, J ^a   Pieniazek, A ^a   Piasecka Zelga, J ^b   Gwozdzinski, K ^a  

^a UNIVERSITY OF LODZ   (Poland)

^b NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

Author keywords

Chemotherapy; Docetaxel; Doxorubicin; Nitroxide; Oxidative stress; Pirolin; Reactive oxygen species; Superoxide dismutase

Indexed keywords

CARBONYL DERIVATIVE; DIMETHYLBENZ[A]ANTHRACENE; DOCETAXEL; DOXORUBICIN; HYDROPEROXIDE; LIPID; NITROXIDE DERIVATIVE; PIROLIN; PLASMA PROTEIN; PROTEIN CARBONYL DERIVATIVE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; THIOL DERIVATIVE; UNCLASSIFIED DRUG;

ANALYTICAL PARAMETERS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; BREAST TUMOR; CANCER COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEPLETION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; ELECTRON SPIN RESONANCE; ENZYME ACTIVITY; FEMALE; IN VIVO STUDY; LIPID BLOOD LEVEL; LIPID PEROXIDATION; NON ENZYMATIC ANTIOXIDANT CAPACITY; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PROTECTION; PROTEIN BLOOD LEVEL; RAT; TREATMENT DURATION;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; BREAST NEOPLASMS; CARCINOGENS; CYCLIC N-OXIDES; DOXORUBICIN; DRUG THERAPY, COMBINATION; FEMALE; HYDROGEN PEROXIDE; OXIDATIVE STRESS; PROTEIN CARBONYLATION; RATS; RATS, SPRAGUE-DAWLEY; SULFHYDRYL COMPOUNDS; SUPEROXIDE DISMUTASE; TAXOIDS; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 84861852995     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (70)

1. Radaideh SM, Sledge GW. Taxane vs. taxane: is the duel at an end? A commentary on a phase-III trial of doxorubicin and docetaxel versus doxorubicin and paclitaxel in metastatic breast cancer: results of the ERASME 3 study. Breast Cancer Res Treat 2008; 111: 203-208.
2. Box V G. The intercalation of DNA double helices with doxorubicin and nogalamycin. J Mol Graph Model 2007; 26: 14-19.
3. Burden DA, Osheroff N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta 1998; 1400: 139-154.
4. Koceva-Chyla A, Jedrzejczak M, Skierski J, Kania K, Jozwiak Z. Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation. Apoptosis 2005; 10: 1497-1514.
5. Swift LP, Rephaeli A, Nudelman A, Phillips DR, Cutts SM. Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res 2006; 66: 4863-4871.
6. Wang S, Konorev EA, Kotamraju S, Joseph J, Kalivendi S, Kalyanaraman B. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H2O2- and p53-dependent pathways. J Biol Chem 2004; 279: 25535-25543.
7. Morse DL, Gray H, Payne CM, Gillies RJ. Docetaxel induces cell death through mitotic catastrophe in human breast cancer cells. Mol Cancer Ther 2005; 4: 1495-1504.
8. Cao D, Qiao B, Ge Z, Yuan Y. Amplification loop cascade for increasing caspase activity induced by docetaxel. J Cell Biochem 2005; 96: 810-820.
9. Peng X, Chen B, Lim CC, Sawyer DB. The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine. Mol Interv 2005; 5: 163-171.
10. Salvatorelli E, Menna P, Cascegna S, et al. Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemotherapies. J Pharmacol Exp Ther 2006; 318: 424-433.
11. Shimoyama M, Murata Y, Sumi K, Hamazoe R, Komuro I. Docetaxel induced cardiotoxicity. Heart 2001; 86: 217-220.
12. Mir O, Alexandre J, Tran A, et al. Relationship between GSTP1 Ile(105)Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. Ann Oncol 2009; 20: 736-740.
13. Damiani E, Kalinska B, Canapa A, et al. The effects of nitroxide radicals on oxidative DNA damage. Free Radic Biol Med 2000; 28: 1257-1265.
14. Zhang R, Goldstein S, Samuni A. Kinetics of superoxide-induced exchange among nitroxide antioxidants and their oxidized and reduced forms. Free Radic Biol Med 1999; 26: 1245-1252.
15. Samuni A, Goldstein S, Russo A, Mitchell JB, Krishna MC, Neta P. Kinetics and mechanism of hydroxyl radical and OH-adduct radical reactions with nitroxides and with their hydroxylamines. J Am Chem Soc 2002; 124: 8719-8724.
16. Offer T, Mohsen M, Samuni A. An SOD-mimicry mechanism underlies the role of nitroxides in protecting papain from oxidative inactivation. Free Radic Biol Med 1998; 25: 832-838.
17. Krishna MC, Samuni A, Taira J, Goldstein S, Mitchell JB, Russo A. Stimulation by nitroxides of catalase-like activity of hemeproteins. Kinetics and mechanism. J Biol Chem 1996; 271: 26018-26025.
18. Yamasaki T, Ito Y, Mito F, et al. Structural concept of nitroxide as a lipid peroxidation inhibitor. J Org Chem 2011; 76: 4144-4148.
19. Koceva-Chyla A, Gwozdzinski K, Kochman A, Stolarska A, Jozwiak Z. Effects of pyrroline and pyrrolidine nitroxides on lipid peroxidation in heart tissue of rats treated with doxorubicin. Cell Mol Biol Lett 2003; 8: 179-183.
20. Koceva-Chyla A, Sokal A, Kania K, Gwozdzinski K, Jozwiak Z. The nitroxides pirolin and pirolid protect the plasma membranes of rat cardiomyocytes against damage induced by anthracyclines. Cell Mol Biol Lett 2003; 8: 171-177.
21. Czepas J, Koceva-Chyla A, Gwozdzinski K, Jozwiak Z. Different effectiveness of piperidine nitroxides against oxidative stress induced by doxorubicin and hydrogen peroxide. Cell Biol Toxicol 2008; 24: 101-112.
22. Chen Y, Jungsuwadee P, Vore M, Butterfield DA, St. Clair DK. Collateral damage in cancer therapy: oxidative stress in nontargeted tissues. Mol Interv 2007; 7: 147-156.
23. Rozantsev EG. Svobodnyje iminoksylnyje radicaly. Moscow: Chimia, 1970.
24. Barros AC, Muranaka EN, Mori LJ, et al. Induction of experimental mammary carcinogenesis in rats with 7,12-dimethylbenz(a)anthracene. Rev Hosp Clin Fac Med Sao Paulo 2004; 59: 257-261.
25. Whitsett T, Carpenter M, Lamartiniere CA. Resveratrol, but not EGCG, in the diet suppresses DMBA-induced mammary cancer in rats. J Carcinog 2006; 5: 15.
26. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82: 70-77.
27. Levine RL, Wehr N, Williams JA, Stadtman ER, Shacter E. Determination of carbonyl groups in oxidized proteins. Meth Mol Biol 2000; 99: 15-24.
28. Misra H, Fridovich I. The role of superoxide anion in the autooxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 1972; 247: 3170-3175.
29. Yamaguchi T, Takamura H, Matoba T, Terao J. HPLC method for evaluation of the free radical-scavenging activity of foods by using 1,1-diphenyl-2-picrylhydrazyl. Biosci Biotechnol Biochem 1998; 62: 1201-1204.
30. Gay C, Gebicki JM. A critical evaluation of the effect of sorbitol on the ferric-xylenol orange hydroperoxide assay. Anal Biochem 2000; 284: 217-220.
31. Rice-Evans CA, Diplock AT, Symons MCR, Burdon RH, Knippenberg PH, (eds). Techniques in Free Radicals Research. Amsterdam, London, Elsevier, 1991.
32. Lowry OH, Rosebrough NG, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-275.
33. Koceva-Chyla A, Sokal A, Kania K, Gwozdzinski K, Jozwiak Z. Protective effect of nitroxides against damage to rat cardiomyocytes treated with doxorubicin. In: Proceedings of XI Biennial Meeting of the Society for Free Radical Research International, C Pasquier (ed.) Bologna, Monduzzi Editore, 2002, pp. 693-696.
34. Minotti G, Saponiero A, Licata S, et al. Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium. Clin Cancer Res 2001; 7: 1511-1515.
35. Aluise CD, Miriyala S, Noel T, et al. 2-Mercaptoethane sulfonate prevents doxorubicin-induced plasma protein oxidation and TNF-α release: Implications for the reactive oxygen species-mediated mechanisms of chemobrain. Free Radic Biol Med 2011; 50: 1630-1638.
36. Mizumachi T, Suzuki S, Naito A, et al. Increased mitochondrial DNA induces acquired docetaxel resistance in head and neck cancer cells. Oncogene 2008; 27: 831-838.
37. Gutierrez PL. The metabolism of quinone-containing alkylating agents: free radical production and measurement. Front Biosci 2000; 5: D629-D638.
38. Szabo C, Ischiropoulos H, Radi R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov 2007; 6: 662-680.
39. Kostoryz EL, Yourtee DM. Oxidative mutagenesis of doxorubicin-Fe(III) complex. Mutat Res 2001; 490: 131-139.
40. Gianni L, Viganò L, Locatelli A, et al. Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer. J Clin Oncol 1997; 15: 1906-1915.
41. Davies MJ, Fu S, Wang H, Dean RT. Stable markers of oxidant damage to proteins and their application in the study of human disease. Free Radic Biol Med 1997; 27: 1151-1163.
42. Dalle-Donne I, Giustarini D, Colombo R, Rossi R, Milzani A. Protein carbonylation in human diseases. Trends Mol Med 2003; 9: 169-176.
43. Gilbert, HF. Molecular and cellular aspects of thiol-disulfide exchange. Adv Enzymol Relat Areas Mol Biol 1990; 63: 69-172.
44. Jonas CR, Puckett AB, Kurtz JC, et al. High-dose chemotherapy decreases plasma glutatione (GSH) in patients undergoing bone marrow transplantion (BMT). FASEB J 1997; 11: A649.
45. Sies H, Akerboom TP. Glutathione (GSSG) efflux from cells and tissues. Methods Enzymol 1984; 105: 445-451.
46. Arner ES, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem 2000; 267: 6102-6109.
47. Kumar B, Koul S, Khandrika L, Meacham RB, Koul HK. Oxidative stress is inherent in prostate cancer cells and is required for aggressive phenotype. Cancer Res 2008; 68: 1777-1785.
48. Pieniazek A, Gwozdzinski K, Bujak S, Luciak M, Zbrug Z. Changes in reducing ability of blond plasma in chronic renal failure patients during hemodialysis. I: Proceedings of XI Biennial Meeting of the Society for Free Radical Research International, C Pasquier (ed.) Bologna, Monduzzi Editore, 2002, pp. 693-696.
49. Young IS. Measurement of total antioxidant capacity. J Clin Pathol 2001; 54: 339.
50. Ozdemir I, Selamoglu Z, Ates B, Gok Y, Yilmaz I. Modulation of DMBA-induced biochemical changes by organoselenium compounds in blood of rats. Indian J Biochem Biophys 2007; 44: 257-259.
51. Gariboldi MB, Rimoldi V, Supino R, Favini E, Monti E. The nitroxide Tempol induces oxidative stress, p21WAF1/CIP1 and cell death in HL60 cells. Free Radic Biol Med 2000; 29: 633-641.
52. Niki E. Lipid peroxidation products as oxidative stress biomarkers. Biofactors 2008; 34: 171-180.
53. Niki E, Yoshida Y, Saito Y, Noguchi N. Lipid peroxidation: mechanisms, inhibition, and biological effects. Biochem Biophys Res Commun 2005; 338: 668-676.
54. Koceva-Chyla A, Kochman A, Glebska J, Gwozdzinski K, Jozwiak Z, Metodiewa D. Tempicol-3, a novel piperidine-N-noxide stable radical and antioxidant, with low toxicity acts as apoptosis inducer and cell proliferation modifier of Yoshida Sarcoma cells in vivo. Anticancer Res 2000; 20: 4611-4618.
55. Dragutan I, Mehlhorn RJ. Modulation of oxidative damage by nitroxide free radicals. Free Radic Res 2007; 41: 303-315.
56. Offer T, Russo A, Samuni A. The pro-oxidative activity of SOD and nitroxide SOD mimics. FASEB J 2000; 14: 1215-1223.
57. Voest EE, van Faassen E, van Asbeck BS, Neijt JP, Marx JJ. Increased hydrogen peroxide concentration in human tumor cells due to a nitroxide free radical. Biochim Biophys Acta 1992; 1136: 113-118.
58. Oliveira PJ, Santos MS, Wallace KB. Doxorubicin-induced thiol-dependent alteration of cardiac mitochondrial permeability transition and respiration. Biochemistry 2006; 71: 194-199.
59. Di Giacomo C, Acquaviva R, Lanteri R, Licata F, Licata A, Vanella A. Nonproteic antioxidant status in plasma of infjects with colon cancer. Exp Biol Med (Maywood) 2003; 228: 525-528.
60. Alshabanah OA, Hafez MM, Al-Harbi MM, et al. Doxorubicin toxicity can be ameliorated during antioxidant L-carnitine supplementation. Oxid Med Cell Longev 2010; 3: 428-433.
61. Oz E, Ilhan MN. Effects of melatonin in reducing the toxic effects of doxorubicin. Mol Cell Biochem 2006; 286: 11-15.
62. Dounousi E, Papavasiliou E, Makedou A, et al. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 2006; 48: 752-760.
63. Aluise CD, St Clair D, Vore M, Butterfield DA. In vivo amelioration of adriamycin induced oxidative stress in plasma by gamma-glutamylcysteine ethyl ester (GCEE). Cancer Lett 2009; 282: 25-29.
64. Yang Z, Fong DW, Yin L, Wong Y, Huang W. Liposomes modulate docetaxel-induced lipid oxidization and membrane damage in human hepatoma cells. J Liposome Res 2009; 19: 122-130.
65. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869-2879.
66. Borisenko GG, Martin I, Zhao Q, Amoscato AA, Kagan VE. Nitroxides scavenge myeloperoxidase-catalyzed thiyl radicals in model systems and in cells. J Am Chem Soc 2004; 126: 9221-9232.
67. Rao NA, van Wolferen ME, Gracanin A, et al. Gene expression profiles of progestin-induced canine mammary hyperplasia and spontaneous mammary tumors. J Physiol Pharmacol 2009; 60(Suppl 1): 73-84.
68. Fan L, Goh BC, Wong CI, et al. Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity. Pharmacogenet Genomics 2008; 18: 623-631.
69. Pawlowski KM, Krol M, Majewska A, et al. Comparison of cellular and tissue transcriptional profiles in canine mammary tumor. J Physiol Pharmacol 2009; 60(Suppl 1): 85-94.
70. Sliwinska A, Sliwinski T, Kasznicki J, Drzewoski J. Effect of gliclazide on nucleotide excision repair (NER) and non-homologous DNA end joining (NHEJ) in normal and cancer cells. J Physiol Pharmacol 2010; 61: 347-353.